Long noncoding RNA <i>SLC2A1‐AS1</i> regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway

Shang, Runze; Wang, Miao; Dai, Bin; Du, Jianbing; Wang, Jianlin; Li, Yi; Qu, Shibin; Yang, Xisheng; Liu, Jingjing; Chen, Xia; Wang, Lin; Wang, Desheng; Liu, Yu

doi:10.1002/1878-0261.12666

Cited by 71 publications

(65 citation statements)

References 38 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some lncRNAs were reported to function as oncogenes or tumor suppressors in different types of cancers including CRC (Jin et al, 2020;Shang et al, 2020;Shen et al, 2020;Wang et al, 2020;Wei et al, 2020;Zheng et al, 2020). only few lncRNAs in CRC have been functionally characterized and the biological function of most of the lncRNAs remains largely unknown.…”

Section: Discussionmentioning

confidence: 99%

Lnc-HSD17B11-1:1 Functions as a Competing Endogenous RNA to Promote Colorectal Cancer Progression by Sponging miR-338-3p to Upregulate MACC1

Zhang

Wang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) play pivotal roles in various kinds of human diseases, especially in cancer. However, regulatory role, clinical significance and underlying mechanisms of lncRNAs in colorectal cancer (CRC) liver metastasis still remain largely unknown. This study aimed to report a novel lncRNA, lnc-HSD17B-11:1, and its functional role in CRC progression. Materials and methods: Differentially expressed lnc-HSD17B11-1:1 was screened and identified from a lncRNA profile microarray. Quantitative real-time PCR was used to determine the expression levels and prognostic values of lncRNA in CRC cohorts. In vitro and in vivo functional experiments were performed to investigate the effects of lnc-HSD17B11-1:1 on tumor growth and metastasis in CRC. Mechanistically, Base Scope, bioinformatics analyses, dual luciferase reporter assay and RNA immunoprecipitation experiments were performed to confirm the association of lnc-HSD17B11-1:1 and miR-338-3p. Dual luciferase reporter assay, qRT-PCR and western blot analysis were performed to assess the relationships among lnc-HSD17B11-1:1, miR-338-3p, and MACC1. Results: Evidently up-regulation of lnc-HSD17B11-1:1 in CRC primary tissues was correlated with the depth of invasion (p = 0.043), clinical stage (p = 0.027), distant metastasis (p = 0.003) and poor prognosis of patients with CRC. lnc-HSD17B11-1:1 promoted CRC cell proliferation, mobility and invasion in vitro and in vivo. Mechanistic analysis revealed that lnc-HSD17B11-1:1 may act as a competing endogenous RNA (ceRNA) by acting as a sponge for miR-338-3p to upregulate the expression of MACC1. Conclusion: These findings suggest that lnc-HSD17B11-1:1 promotes CRC progression through lnc-HSD17B11-1:1/miR-338-3p/MACC1 axis and this might serve as a new diagnostic marker or target for treatment of CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Lnc-HSD17B11-1:1 Functions as a Competing Endogenous RNA to Promote Colorectal Cancer Progression by Sponging miR-338-3p to Upregulate MACC1

Zhang

Wang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Therefore, any cause of hepatocyte proliferation may lead to the occurrence of HCC. In recent years, lncRNAs have become a focus of tumorrelated research, and there are a lot of evidences that they can participate in the modulation of cancer cell migration, proliferation and apoptosis [18][19][20][21]. Here, TMEM220-AS1 was selectedby analyzing the TCGA database which was poorly expressed in HCC samples and was associated with clinical staging and survival prognosis.…”

Section: Discussionmentioning

confidence: 99%

Long Non-Coding RNA TMEM220-AS1 Suppressed Hepatocellular Carcinoma by Regulating the miR-484/MAGI1 Axis as a Competing Endogenous RNA

Cao

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundLong non-coding RNA has a considerable regulative influence in multiple biological processes. Nevertheless, the role of TMEM220-AS1 in hepatocellular carcinoma (HCC) remains unclear.MethodsWe used the TCGA database to analyze differentially expressed lncRNAs. qRT-PCR was used to verify the results in a large population. Afterwards, in vitro effects of TMEM220-AS1 on HCC cells were determined by CCK-8, EdU, Flow cytometry experiment and transwell assays in HCC cells. We adopted qRT-PCR, western blot to identify epithelial-mesenchymal transition (EMT). Moreover, we adopted bioinformatics analysis, western blot, dual luciferase reporter gene assay and RIP to investigate underlying molecular mechanisms of TMEM220-AS1 function. Finally, the function of TMEM220-AS1 was verified in vivo.ResultsTMEM220-AS1 was remarkably decreasedin HCC. It was demonstrated that malignant phenotypes and EMT of HCC cells were promoted by knocking TMEM220-AS1 down both in vivo and in vitro. TMEM220-AS1, which was detected distributing mainly in the cytoplasm, worked as a miRNA sponge to sponge miR-484 and promote the level of MAGI1, therefore curbed malignant phenotypes of HCC cells.ConclusionsIn conclusion, downregulation of TMEM220-AS1promotes HCC through miR-484/MAGI1 axis.

show abstract

“…LncRNA-p23154 promotes glycolysis in oral squamous cell carcinoma by binding to the promoter region of miR-378a-3p, which represses GLUT1 expression by targeting to its 3'UTR directly [53]. SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma by competitively binding to STAT3 and resulting in inactivation of the FOXM1/GLUT1 axis [54]. Consistent with these studies, we showed that GAS6-AS1 exerted its role in tumor progression and glucose metabolism in LUAD via downregulating GLUT1.…”

Section: Discussionmentioning

confidence: 99%

Long Noncoding RNA GAS6-AS1 Inhibits Progression and Glucose Metabolism Reprogramming in Lung Adenocarcinoma Via Repressing E2F1-Mediated Transcription of GLUT1

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundGlucose metabolism reprogramming is one of the hallmarks of cancer cells. While functional and regulatory mechanism of long noncoding RNA (lncRNA) in the contribution of glucose metabolism in lung adenocarcinoma (LUAD) remains incompletely understood. The aim of this study was to uncover the roles for GAS6-AS1 in the regulation of progression and glucose metabolism in LUAD.MethodsThe tumor-suppressive function of GAS6-AS1 was determined by experiments in vitro and nude mice xenograft models. The role of GAS6-AS1 in regulating cancer glucose metabolism was proved by detecting glucose uptake, lactate production, pyruvate production and extracellular acidification rate (ECAR). RNA pull-down assay, RNA immunoprecipitation (RIP) assay, luciferase reporter assay and Chromatin Immunoprecipitation (ChIP) assay were used to identify the underlying molecular mechanisms of GAS6-AS1. And the expression level of GAS6-AS1 in LUAD tissues and cells was measured by quantitative real-time PCR.ResultsOverexpression of GAS6-AS1 suppressed tumor progression of LUAD both in vitro and in vivo. Metabolic-related assays revealed that GAS6-AS1 inhibited glucose metabolism reprogramming. Mechanically, GAS6-AS1 was found to repress the expression of glucose transporter GLUT1, a key regulator of glucose metabolism. Ectopic expression of GLUT1 restored the inhibition effect of GAS6-AS1 on cancer progression and glucose metabolism reprogramming. Further investigation identified that GAS6-AS1 directly interacted with transcription factor E2F1 and suppressed E2F1-mediated transcription of GLUT1. And GAS6-AS1 was downregulated in LUAD tissues and correlated with clinicopathological characteristics and survival of patients.ConclusionsTaken together, our results identified GAS6-AS1 as a novel tumor suppressor in LUAD and unraveled its underlying molecular mechanism in reprogramming glucose metabolism. GAS6-AS1 potentially served as a prognostic marker and therapeutic target in LUAD.

show abstract

Long noncoding RNA SLC2A1‐AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway

Cited by 71 publications

References 38 publications

Lnc-HSD17B11-1:1 Functions as a Competing Endogenous RNA to Promote Colorectal Cancer Progression by Sponging miR-338-3p to Upregulate MACC1

Lnc-HSD17B11-1:1 Functions as a Competing Endogenous RNA to Promote Colorectal Cancer Progression by Sponging miR-338-3p to Upregulate MACC1

Long Non-Coding RNA TMEM220-AS1 Suppressed Hepatocellular Carcinoma by Regulating the miR-484/MAGI1 Axis as a Competing Endogenous RNA

Long Noncoding RNA GAS6-AS1 Inhibits Progression and Glucose Metabolism Reprogramming in Lung Adenocarcinoma Via Repressing E2F1-Mediated Transcription of GLUT1

Contact Info

Product

Resources

About